Compare · NVS vs XENE
NVS vs XENE
Side-by-side comparison of Novartis AG (NVS) and Xenon Pharmaceuticals Inc. (XENE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and XENE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $279.39B, about 56.4x XENE ($4.95B).
- Over the past year, NVS is up 24.1% and XENE is up 63.0% - XENE leads by 38.8 points.
- XENE has hit the wire 23 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 19 for XENE).
- Company
- Novartis AG
- Xenon Pharmaceuticals Inc.
- Price
- $146.50-1.72%
- $51.21-0.95%
- Market cap
- $279.39B
- $4.95B
- 1M return
- +0.71%
- -8.47%
- 1Y return
- +24.12%
- +62.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 23
- Recent ratings
- 25
- 19
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG
Latest XENE
- Director Patou Gary sold $70,251 worth of shares (1,322 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 24,896 units (SEC Form 4) to cover withholding tax
- Director Cannon Gillian sold $63,237 worth of shares (1,190 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 45% to 1,455 units (SEC Form 4) to satisfy tax liability
- SEC Form 144 filed by Xenon Pharmaceuticals Inc.
- Director Patou Gary converted options into 2,645 shares, increasing direct ownership by 11% to 26,218 units (SEC Form 4)
- Director Machado Patrick converted options into 2,645 shares (SEC Form 4)
- Director Gover Justin D. converted options into 2,645 shares (SEC Form 4)
- Director Garofalo Elizabeth A. converted options into 2,645 shares (SEC Form 4)
- Director Gannon Steven converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 12% to 11,870 units (SEC Form 4) to cover withholding tax
- Director Cannon Gillian converted options into 2,645 shares (SEC Form 4)
- Director Svoronos Dawn converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 5% to 26,229 units (SEC Form 4) to satisfy withholding tax